Case Reports
Vol. 3 No. 1 (2011): Reviews, Articles, Case Reports and Letters
5-Azacytidine in chronic myelomonocytic leukemia: case report and review of literature
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: March 14, 2011
2617
Views
736
Downloads
1095
HTML
Hematology
Authors
Hypomethylating drugs are useful in the management of Myelodysplastic syndromes, but there are only few reports on chronic myelomonocycitic (CMML) leukemia patients. We describe our experience in 3 CMML patients treated with azacitidine. Two patients obtained partial response after 4 treatment cycles with only minor toxicity and are in continuous partial response, with stable peripheral blood counts, at 29 and 30 cycles from treatment start.
Downloads
Download data is not yet available.
Citations
Ethics Approval
Case ReportHow to Cite
“5-Azacytidine in chronic myelomonocytic leukemia: case report and review of literature” (2011) Mediterranean Journal of Hematology and Infectious Diseases, 3(1), p. e2011011. doi:10.4084/mjhid.2011.011.
